用于舌下接种抗A组链球菌的模块化病毒样颗粒
本研究评估基于携带J8肽的免疫原性模块化病毒样颗粒(J8-VLPs)的舌下冻干制剂作为安全经济的A组链球菌(GAS)疫苗。小鼠舌下给予J8-VLPs后,J8-VLPs引流至下颌下淋巴结并快速吸收入体循环,诱导高血清IgG及唾液IgA,且Th1/Th2平衡良好;共给予黏膜佐剂霍乱毒素(CT)进一步增强唾液IgA,冻干与非冻干制剂效果相当,小鼠唾液在体外具调理GAS活性。作者认为该舌下冻干模块化VLP制剂可在流行区以经济有效方式预防和控制GAS疾病。
要点
- 舌下J8-VLPs可引流至下颌下淋巴结并快速吸收入血,支持系统与黏膜免疫诱导。
- 舌下J8-VLPs诱导高血清IgG、良好Th1/Th2平衡及高唾液IgA。
- 共给予CT增强唾液IgA,冻干与非冻干J8-VLPs效果相当,唾液具体外调理GAS活性。
核心结论
- 舌下递送微生物生产的模块化VLP冻干制剂可在流行区以经济有效方式预防和控制GAS疾病。
研究设计与样本
- 本研究为动物实验,评估基于携带J8肽的模块化病毒样颗粒(J8-VLPs)的舌下冻干制剂作为GAS疫苗。
主要发现
- 体内示踪显示舌下J8-VLPs引流至下颌下淋巴结,并快速吸收入体循环。
- 舌下给予J8-VLPs诱导高血清IgG抗体水平,Th1与Th2免疫应答平衡良好。
- 舌下接种J8-VLPs诱导高水平唾液IgA抗体。
- 共给予黏膜佐剂霍乱毒素(CT)进一步增强J8-VLPs制剂诱导的唾液IgA抗体水平升高。
- 给予CT佐剂的J8-VLPs冻干制剂(FD-J8-VLPs)与J8-VLPs非冻干制剂后,唾液IgA和血清IgG水平相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infection with Group A streptococcus (GAS)-an oropharyngeal pathogen-leads to mortality and morbidity, primarily among developing countries and indigenous populations in developed countries. The development of safe and affordable GAS vaccines is challenging, due to the presence of various unique GAS serotypes, antigenic variation within the same serotype, and potential auto-immune responses. In the present study, we evaluated the use of a sublingual freeze-dried (FD) formulation based on immunogenic modular virus-like particles (VLPs) carrying the J8 peptide (J8-VLPs) as a potential safe and cost-effective GAS vaccine for inducing protective systemic and mucosal immunity. By using in vivo tracing of the sublingual J8-VLPs, we visualized the draining of J8-VLPs into the submandibular lymph nodes, in parallel with its rapid absorption into the systemic circulation, which support the induction of effective immune responses in both systemic and mucosal compartments. The sublingual administration of J8-VLPs resulted in a high serum IgG antibody level, with a good balance of Th1 and Th2 immune responses. Of note, sublingual vaccination with J8-VLPs elicited high levels of IgA antibody in the saliva. The co-administration of mucosal adjuvant cholera toxin (CT) further enhanced the increase in salivary IgA antibody levels induced by the J8-VLPs formulation. Moreover, the levels of salivary IgA and serum IgG observed following the administration of the CT-adjuvanted FD formulation of J8-VLPs (FD-J8-VLPs) and non-FD formulation of J8-VLPs were comparable. In fact, the saliva isolated from mice immunized with J8-VLPs and FD-J8-VLPs with CT demonstrated opsonizing activity against GAS in vitro. Thus, we observed that the sublingually delivered FD formulation of microbially produced modular VLPs could prevent and control GAS diseases in endemic areas in a cost-effective manner.
引用
- Seth A, Kong IG, Lee SH, et al. Modular virus-like particles for sublingual vaccination against group A streptococcus. Vaccine. 2016. PMID: 27866769. doi:10.1016/j.vaccine.2016.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。